6 research outputs found

    A Study on a high-precision linear motion table with magnetic bearing suspension

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :๊ธฐ๊ณ„์„ค๊ณ„ํ•™๊ณผ,1997.Docto

    A study on the effects of position move on individual compensation

    No full text
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ํ–‰์ •๋Œ€ํ•™์› : ๊ณต๊ธฐ์—…์ •์ฑ…ํ•™๊ณผ, 2015. 8. ๊ถŒ์ผ์›….์ธ์ ์ž์› ๊ด€๋ฆฌ๋Š” ํ˜„๋Œ€ ์กฐ์ง์˜ ์„ฑ๊ณผ์— ์žˆ์–ด ํ•ต์‹ฌ์ ์ธ ์—ญํ• ์„ ์ˆ˜ํ–‰ํ•˜๋Š” ๊ฒƒ์œผ๋กœ ์—ฌ๊ฒจ์ง€๊ณ  ์žˆ๋‹ค. ์ธ๊ฐ„ ์ž์ฒด๊ฐ€ ์กฐ์ง์˜ ์ค‘์š”ํ•œ ๋™๋ ฅ์ด์ž ์ž์›์œผ๋กœ์„œ ์ธ์‹๋˜๊ณ  ์žˆ์œผ๋ฉฐ ์ธ์ ์ž์›์„ ์–ด๋–ป๊ฒŒ ๊ด€๋ฆฌํ•˜๊ณ  ๊ฐœ๋ฐœํ•˜๋Š๋ƒ๊ฐ€ ์กฐ์ง์„ฑ๊ณผ๋ฅผ ๊ทน๋Œ€ํ™”ํ•˜๋Š”๋ฐ ๊ฒฐ์ •์ ์ธ ์—ญํ• ์„ ํ•  ์ˆ˜ ์žˆ๋‹ค๊ณ  ์—ฌ๊ฒจ์ง„๋‹ค. ์ด๋Ÿฐ ๊ด€์ ์—์„œ ์กฐ์ง์˜ ์„ฑ๊ณผ๋ฅผ ๊ทน๋Œ€ํ™”ํ•˜๊ธฐ ์œ„ํ•œ ์ธ์ ์ž์› ๊ด€๋ฆฌ๋ฐฉ์•ˆ์„ ์ฐพ๊ธฐ ์œ„ํ•œ ์—ฐ๊ตฌ์™€ ๋…ธ๋ ฅ์ด ํ™œ๋ฐœํ•˜๊ฒŒ ์ง„ํ–‰๋˜๊ณ  ์žˆ์œผ๋‚˜ ์ด๋Ÿฌํ•œ ์—ฐ๊ตฌ์˜ ๋Œ€๋ถ€๋ถ„์€ ๋ฏผ๊ฐ„์˜์—ญ ์กฐ์ง์— ์ดˆ์ ์ด ๋งž์ถฐ์ ธ ์žˆ๋‹ค. 1980๋…„๋Œ€ ์ดํ›„ ์‹ ๊ณต๊ณต๊ด€๋ฆฌ๋ก ์˜ ๋Œ€๋‘์ดํ›„ ๊ณต๊ณต๋ถ€๋ฌธ์—๋„ ์ธ์ ์ž์›๊ด€๋ฆฌ์— ๋Œ€ํ•œ ๊ด€์‹ฌ์ด ๊ธ‰์ฆํ–ˆ์ง€๋งŒ, ์ด๋Š” ์ „ํ†ต์ ์ธ ๊ณต๋ฌด์› ์กฐ์ง์— ๋Œ€ํ•œ ์—ฐ๊ตฌ๋กœ ๊ตญํ•œ๋˜์—ˆ๋‹ค. ๊ณต๊ธฐ์—…์€ ๋ฏผ๊ฐ„๋ถ€๋ฌธ๊ณผ ๊ณต๊ณต๋ถ€๋ฌธ์˜ ํŠน์ง•์„ ๋ชจ๋‘ ๋‚˜ํƒ€๋‚˜๋Š” Hybrid ์กฐ์ง์œผ๋กœ์„œ ๋งค์šฐ ํŠน์ˆ˜ํ•œ ์„ฑ๊ฒฉ์„ ๊ฐ–๋Š” ์กฐ์ง์ด๋‹ค. ์ „ํ†ต์ ์ธ ๊ณต๋ฌด์› ์กฐ์ง๊ณผ๋„ ์ฐจ์ด๋ฅผ ๋ณด์ด๋ฉฐ, ๋˜ํ•œ ๋ฏผ๊ฐ„๊ธฐ์—…๊ณผ๋„ ์ฐจ์ด๋ฅผ ๋ณด์ธ๋‹ค. ๋”ฐ๋ผ์„œ ๊ณต๊ธฐ์—…์— ์ ํ•ฉํ•œ ์ธ์‚ฌ๊ด€๋ฆฌ์ฒด๊ณ„์™€ ์ธ์‚ฌ์›์น™์„ ์ˆ˜๋ฆฝํ•  ํ•„์š”๊ฐ€ ์žˆ์œผ๋ฉฐ, ์ด๋Š” ํ˜„์ƒ์— ๋Œ€ํ•œ ์‹ค์ฆ์  ์—ฐ๊ตฌ๊ฐ€ ์„ ํ–‰๋˜์–ด์•ผ ๊ฐ€๋Šฅํ•  ๊ฒƒ์ด๋‹ค. ๋ณธ ์—ฐ๊ตฌ๋Š” ์ด๋Ÿฌํ•œ ๋ฌธ์ œ์˜์‹ ์†์—์„œ ์‹œ์ž‘๋˜์—ˆ์œผ๋ฉฐ, ์‹ค์ฆ์  ์—ฐ๊ตฌ๋ฅผ ํ†ตํ•ด ๊ณต๊ธฐ์—…์˜ ์กฐ์ง์šด์˜ ๋ฉ”์ปค๋‹ˆ์ฆ˜์„ ๋ฐ˜์˜ํ•œ ์ธ์‚ฌ๊ด€๋ฆฌ์ฒด๊ณ„ ๊ตฌ์ถ•์˜ ํ† ๋Œ€๊ฐ€ ๋  ์ˆ˜ ์žˆ์„ ๊ฒƒ์ด๋‹ค. ๋ณธ ์—ฐ๊ตฌ์—์„œ๋Š” K๊ณต๊ธฐ์—…์˜ 2002๋…„โˆผ2005๋…„ ์ž…์‚ฌํ•œ 4์ง๊ธ‰ ์ง์›๊ณผ ๋™๊ธฐ๊ฐ„์— 3์ง๊ธ‰ ๋ฐ 2์ง๊ธ‰์œผ๋กœ ์Šน์ง„ํ•œ ์ง์› ์ด 3,408๋ช…์˜ ๋ณด์ง์ด๋™ ํšŸ์ˆ˜์™€ ํ˜•ํƒœ๋ฅผ ์ตœ๋Œ€ 10๋…„์˜ ๊ธฐ๊ฐ„๋™์•ˆ ์ถ”์ ํ•˜์—ฌ ์ด๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ ๋ณด์ง๊ฒฝ๋กœ๋ฅผ ์œ ํ˜•ํ™”ํ•˜๊ณ , ์ด๋Ÿฌํ•œ ์œ ํ˜•์ด ๊ฐœ์ธ์— ๋Œ€ํ•œ ๋ณด์ƒ์— ์–ด๋–ค ๊ด€๊ณ„๋ฅผ ๊ฐ–๋Š”์ง€ ๋ถ„์„ํ•˜์˜€๋‹ค. ๋ณด์ง์ด๋™์˜ ์œ ํ˜•ํ™”๋Š” ์„ธ๊ฐ€์ง€ ๊ด€์ ์—์„œ ์ง„ํ–‰ํ•˜์˜€๋Š”๋ฐ, ์ฒซ์งธ ์ผ์ •๊ธฐ๊ฐ„์„ ์„ค์ •ํ•˜๊ณ  ํ•ด๋‹น๊ธฐ๊ฐ„ ์ค‘ ๋ณด์ง์ด๋™์ด ์–ด๋Š ์‹œ๊ธฐ์— ์ง‘์ค‘๋˜๋Š”์ง€๋ฅผ ๋ถ„์„ํ•จ์œผ๋กœ์จ ๋ณด์ง๊ฒฝ๋กœ ์œ ํ˜•์„ ์ •์˜ํ•˜์˜€๊ณ , ๋‘˜์งธ, ์กฐ์ง์ฒด๊ณ„ ์†์—์„œ ์–ด๋– ํ•œ ๋ฒ”์œ„๋กœ ์ด๋™ํ•˜์˜€๋Š”์ง€๋ฅผ ๋ฐ”ํƒ•์œผ๋กœ ๋ณด์ง์˜ ์ด๋™์œ ํ˜•์„ ์ •์˜ํ•˜์—ฌ ๋ถ„๋ฅ˜ํ•˜์˜€๋‹ค. ์…‹์งธ, ์กฐ์ง์˜ ๊ธฐ๋Šฅ์— ๋”ฐ๋ผ ๋ณด์ง๋ณ„๋กœ ์—…๋ฌด์˜ ์ค‘์š”๋„๋ฅผ ๊ตฌ๋ถ„ํ•˜๊ณ  ํ•ด๋‹น ๋ณด์ง์„ ๊ฒฝํ—˜ํ•˜์˜€๋Š”๊ฐ€๋ฅผ ํ†ตํ•ด ์—…๋ฌด์ค‘์š”๋„๋ณ„ ๋ณด์ง์œ ํ˜•์„ ์ •์˜ํ•˜์—ฌ ๋ถ„๋ฅ˜ํ•˜์˜€๋‹ค. ์•ž์„œ ๋ถ„๋ฅ˜๋œ ์œ ํ˜•์„ ๋ฐ”ํƒ•์œผ๋กœ ์ด๋™ํšŸ์ˆ˜ ๋ฐ ๊ฐ๊ฐ์˜ ์œ ํ˜•์ด ์Šน์ง„์—ฌ๋ถ€, ์Šน์ง„์†Œ์š”๊ธฐ๊ฐ„, ๊ธฐ๋ณธ์—ฐ๋ด‰์ˆ˜์ค€๊ณผ ์–ด๋– ํ•œ ๊ด€๊ณ„๋ฅผ ๊ฐ–๋Š”์ง€ ํƒ์ƒ‰์  ์—ฐ๊ตฌ๋ฅผ ์ˆ˜ํ–‰ํ•˜์˜€๋Š”๋ฐ, ์ง๊ธ‰๋งˆ๋‹ค ํŽธ์ฐจ๋ฅผ ๋ณด์ด๊ธฐ๋Š” ํ•˜์ง€๋งŒ ๋Œ€์ฒด์ ์œผ๋กœ ๋ณด์ง์ด๋™ ํšŸ์ˆ˜์˜ ๊ฒฝ์šฐ ๊ทธ ์ž์ฒด๋กœ์„œ ์œ ์˜๋ฏธํ•œ ๊ฐ’์„ ๋ณด์ด์ง€ ์•Š์•˜์œผ๋ฉฐ, ๋ณด์ง๊ฒฝ๋กœ ์œ ํ˜•์˜ ๊ฒฝ์šฐ ํ•ด๋‹น์ง๊ธ‰ ์ „๋ฐ˜๊ธฐ์— ๋‹ค์–‘ํ•œ ๋ณด์ง์„ ๊ฒฝํ—˜ํ•œ ํ›„ ์ „๋ฌธํ™”๋˜๋Š” ์œ ํ˜•์ด ๋†’์€ ๋ณด์ƒ์„ ๋ฐ›๋Š”๋‹ค๋Š” ์ ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ๋‹ค. ๋˜ํ•œ ์กฐ์ง๊ตฌ์กฐ์ƒ ์–ด๋Š๋ฒ”์œ„์˜ ์ด๋™์„ ๊ฒฝํ—˜ํ•˜์˜€๋Š๋ƒ์˜ ๊ด€์ ์—์„œ ์œ ํ˜•ํ™”ํ•œ ๋ณด์ง์˜ ์ด๋™์œ ํ˜•๊ณผ ๋ณด์ƒ๊ณผ์˜ ๊ด€๊ณ„๋Š” ๋„“์€ ๋ฒ”์œ„์˜ ์ด๋™์„ ์˜๋ฏธํ•˜๋Š” ๊ด€์™ธ๋กœ์˜ ์ด๋™์˜ ๊ฒฝ์šฐ ํฐ ์˜๋ฏธ๋ฅผ ๊ฐ–์ง€ ์•Š์œผ๋‚˜, ์ผ๋‹จ ๊ด€์™ธ์ด๋™ํ•œ ์ดํ›„ ๊ด€๋‚ด์—์„œ ์ผ์ •ํ•˜๊ฒŒ ๋ณด์ง์„ ์œ ์ง€ํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ์žฆ์€ ์ด๋™์„ ๊ฒฝํ—˜ํ•˜๋Š” ๊ฒฝ์šฐ๋ณด๋‹ค ๋ณด์ƒ์ˆ˜์ค€์ด ๋†’์Œ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ๋‹ค. ์—…๋ฌด์ค‘์š”๋„๋ณ„ ๋ณด์ง์œ ํ˜•์˜ ๊ฒฝ์šฐ๋Š” ๋ณด๋‹ค ์ค‘์š”ํ•œ ์—…๋ฌด๋ฅผ ์ˆ˜ํ–‰ํ•˜๋Š” ์กฐ์ง์„ ๊ฒฝํ—˜ํ•˜๋Š” ๊ฒฝ์šฐ๊ฐ€ ๊ทธ๋ ‡์ง€ ์•Š์€ ๊ฒฝ์šฐ๋ณด๋‹ค ๋†’์€ ๋ณด์ƒ์ˆ˜์ค€์„ ๋ณด์—ฌ์ฃผ์—ˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ๋Š” ๋ณด์ง๊ด€๋ฆฌ์™€ ๋ณด์ƒ๊ณผ์˜ ๊ด€๊ณ„๋ฅผ ํƒ์ƒ‰ํ•จ์œผ๋กœ์จ ๊ณต๊ธฐ์—… ์—ญ์‹œ ์ ๊ทน์ ์ธ ๋ณด์ง๊ด€๋ฆฌ์™€ CDP ๊ฐœ๋ฐœ์„ ํ†ตํ•ด ์กฐ์ง์˜ ์„ฑ๊ณผ๋ฅผ ๊ทน๋Œ€ํ™”์‹œ์ผœ์•ผ ํ•œ๋‹ค๋Š” ์‹œ์‚ฌ์ ์„ ๋˜์ง€๊ณ  ์žˆ์œผ๋ฉฐ, ์ค‘์š”๋„๊ฐ€ ๋†’์€ ์ง๋ฌด์˜ ์ˆ˜ํ–‰์ด ๋†’์€ ๋ณด์ƒ์œผ๋กœ ์—ฐ๊ฒฐ๋  ์ˆ˜ ์žˆ๋‹ค๋Š” ์ ์—์„œ ํ–ฅํ›„ ๊ณต๊ธฐ์—…์˜ ์ธ์‚ฌ๊ด€๋ฆฌ์ฒด๊ณ„์— ๋Œ€ํ•œ ๋ฐฉํ–ฅ์„ ๋ณด์—ฌ์ค€๋‹ค.์ œ 1 ์žฅ ์„œ๋ก  1 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ์˜ ๋ฐฐ๊ฒฝ ๋ฐ ๋ชฉ์  1 ์ œ 2 ์ ˆ ์—ฐ๊ตฌ๋Œ€์ƒ ๋ฐ ๋ฒ”์œ„ 4 ์ œ 2 ์žฅ ์ด๋ก ์  ๋ฐฐ๊ฒฝ ๋ฐ ์„ ํ–‰์—ฐ๊ตฌ 6 ์ œ 1 ์ ˆ ์ธ์ ์ž์›๊ด€๋ฆฌ 6 ์ œ 2 ์ ˆ ๋ณด์ง์ด๋™ 9 ์ œ 3 ์ ˆ ๋ณด์ง๊ด€๋ฆฌ 10 1. ์ˆœํ™˜๋ณด์ง์ œ 12 2. ์ „๋ฌธ๋ณด์ง์ œ 13 3. ๋ณด์ง๊ธฐ๊ฐ„๊ณผ ์„ฑ๊ณผ์™€์˜ ๊ด€๊ณ„ 15 ์ œ 4 ์ ˆ ์ง๋ฌด์„ฑ๊ณผ 16 1. ์ง๋ฌด์„ฑ๊ณผ์˜ ํ‰๊ฐ€ 17 2. ์„ฑ๊ณผ์— ๋Œ€ํ•œ ๋ณด์ƒ 18 ์ œ 3 ์žฅ ์—ฐ๊ตฌ๋ฐฉ๋ฒ•๋ก  21 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ๋ฌธ์ œ ๋ฐ ๋ชจํ˜• 21 1. ์—ฐ๊ตฌ๋ฌธ์ œ 21 2. ์—ฐ๊ตฌ๋ชจํ˜• 22 ์ œ 2 ์ ˆ ๋ณ€์ˆ˜์˜ ์กฐ์ž‘์  ์ •์˜ 24 1. ๋ณด์ง์ด๋™ ํšŸ์ˆ˜ 24 2. ๋ณด์ง๊ฒฝ๋กœ ์œ ํ˜• 24 3. ๋ณด์ง์˜ ์ด๋™์œ ํ˜• 25 4. ์—…๋ฌด์ค‘์š”๋„๋ณ„ ๋ณด์ง์œ ํ˜• 25 5. ์Šน์ง„์—ฌ๋ถ€ 26 6. ์Šน์ง„์†Œ์š”๊ธฐ๊ฐ„ 26 7. ํ‰๊ฐ€๊ฒฐ๊ณผ์— ๋”ฐ๋ฅธ ๊ธฐ๋ณธ์—ฐ๋ด‰ ์ˆ˜์ค€ 27 8. ํ†ต์ œ๋ณ€์ˆ˜ 27 ์ œ 3 ์ ˆ ์กฐ์‚ฌ์„ค๊ณ„ 29 ์ œ 4 ์žฅ ๋ถ„์„๊ฒฐ๊ณผ 30 ์ œ 1 ์ ˆ ๊ธฐ์ดˆํ†ต๊ณ„ ๋ถ„์„ 30 1. ์ข…์†๋ณ€์ˆ˜์˜ ๊ธฐ์ˆ ํ†ต๊ณ„๋Ÿ‰ 30 2. ๋…๋ฆฝ๋ณ€์ˆ˜์˜ ๊ธฐ์ˆ ํ†ต๊ณ„๋Ÿ‰ 32 3. ํ†ต์ œ๋ณ€์ˆ˜์˜ ๊ธฐ์ˆ ํ†ต๊ณ„๋Ÿ‰ 33 ์ œ 2 ์ ˆ ๋ณด์ง์ด๋™์˜ ์œ ํ˜•๋ถ„์„ 36 1. ๋ณด์ง์ด๋™ Data ๋ถ„์„์„ ํ†ตํ•œ ์œ ํ˜•ํ™” 36 2. ๋ณด์ง์˜ ๊ฒฝ๋กœ์œ ํ˜• 37 3. ๋ณด์ง์˜ ์ด๋™์œ ํ˜• 40 4. ์—…๋ฌด์ค‘์š”๋„๋ณ„ ๋ณด์ง์œ ํ˜• 44 ์ œ 3 ์ ˆ ํšŒ๊ท€๋ถ„์„ ๊ฒฐ๊ณผ 46 1. ๋ณด์ง์ด๋™ ํšŸ์ˆ˜์™€ ๋ณด์ƒ๊ณผ์˜ ๊ด€๊ณ„ ๋ถ„์„ 46 2. ๋ณด์ง์ด๋™ ๊ฒฝ๋กœ์œ ํ˜•๊ณผ ๋ณด์ƒ๊ณผ์˜ ๊ด€๊ณ„๋ถ„์„ 56 3. ๋ณด์ง์˜ ์ด๋™์œ ํ˜•๊ณผ ๋ณด์ƒ๊ณผ์˜ ๊ด€๊ณ„๋ถ„์„ 68 4. ์—…๋ฌด์ค‘์š”๋„์— ๋”ฐ๋ฅธ ๋ณด์ง์œ ํ˜•๊ณผ ๋ณด์ƒ๊ณผ์˜ ๊ด€๊ณ„๋ถ„์„ 78 ์ œ 5 ์žฅ ๊ฒฐ๋ก  89 ์ œ 1 ์ ˆ ์—ฐ๊ตฌ๊ฒฐ๊ณผ ์š”์•ฝ 89 ์ œ 2 ์ ˆ ์—ฐ๊ตฌ์˜ ์‹œ์‚ฌ์  ๋ฐ ์ •์ฑ…์  ํ•จ์˜ 93 ์ œ 3 ์ ˆ ์—ฐ๊ตฌ์˜ ํ•œ๊ณ„ ๋ฐ ํ–ฅํ›„ ์—ฐ๊ตฌ๊ณผ์ œ 95 ์ฐธ๊ณ ๋ฌธํ—Œ 97 Abstract 99Maste

    Preparation of biocompatible nanocarriers encapsulating fluorescent precursors for cancer targeting

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ์œตํ•ฉ๊ณผํ•™๊ธฐ์ˆ ๋Œ€ํ•™์› ์œตํ•ฉ๊ณผํ•™๋ถ€, 2018. 2. ์ด๊ฐ•์›.Nanomedicine based on nanotechnology facilitates the development of both therapeutic and diagnostic agents. Especially, fluorescence-based imaging guidance for tumor resection has recently emerged as a fascinating tool using exogenous fluorescent contrast agents with objective and precise information of tumor tissues. However, the most contrast agents cannot inherently offer real-time visual information concerning selectivity and localization of the tumor because of a lack of cancer targeting property and insufficient sensitivity for acquiring fluorescent signal in real-time. For selective and active tumor targeting, these contrast agents were chemically conjugated with targeting moieties such as antibodies and peptides, which often fail in Food and Drug Administration (FDA) approval due to safety issues. Motivated by this point, we have developed nanocarriers to escape the most issues in regard to the clinical safety. In this study, we have demonstrated selective targeting of cancer cells (including in vivo xenograft models) and targeted turn-on fluorescence upon delivery of nanocarriers to achieve excellent sensitivity with high signal-to-noise ratio. Owing to the non-toxic and distinct fluorescence, we expect that our nanocarriers developed in this study will be extremely fast to be exploited for clinical use.Chapter 1 Introduction 1 Chapter 2 Experimental Methods . 3 Chapter 3 Results and Discussion 14 Chapter 4 Conclusion 22 References 23 Figures 28 Publication List 48 ์ดˆ๋ก (๊ตญ๋ฌธ) 49Maste
    corecore